Previous 10 | Next 10 |
2023-04-27 09:47:28 ET Evaxion Biotech ADS press release ( EVAX ): Q4 GAAP EPS of -$0.98. As of December 31, 2022, cash and cash equivalents were $13.2 million as compared to $32.2 million as of December 31, 2021. Research and Development expenses were $17.1 million f...
Evaxion presented promising data from its Phase 1/2a clinical trial of EVX-02 in patients with late-stage melanoma at the 2023 AACR meeting EVX-03, a DNA-based personalized cancer vaccine, is expected to have a CTA filing in Q3 2023 and start a Phase 1 trial in solid tumor patients in Q4 2023...
2023-04-18 08:30:29 ET China Jo-Jo Drugstores ( CJJD ) -36% . Athersys ( ATHX ) -33% announces $3.7 million registered direct Offering and concurrent private placement. Presto Automation ( PRST ) -20% . Evaxion Biotech ( EVAX ) -20% promis...
2023-04-17 08:21:00 ET CNS Pharmaceuticals ( CNSP ) +72% . Presto Automation ( PRST ) +55% . Prometheus Biosciences ( RXDX ) +70% soars 70%, Merck dips after ~$11B buyout deal. Dragonfly Energy ( DFLI ) +49% . Kiromic BioPharma ( ...
2023-04-13 10:02:55 ET Gainers: Ocean Biomedical ( OCEA ) +24% . ContraFect ( CFRX ) +21% . bluebird bio ( BLUE ) +18% . Evaxion Biotech ( EVAX ) +17% . Hillstream BioPharma ( HILS ) +10% . Losers: GlucoTrack ( GCTK ) ...
COPENHAGEN, Denmark, April 13, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in AI-powered immunotherapies, announces the successful publication in Frontiers of Immunology of preclinical data demonstrating the effectiveness of its...
New AI discovery de-risking the pipeline through faster validation and has potential to enter clinical Phase 1/2a in Q4 2023 Phase 2b clinical trial reduced in size and expected to reach interim data on time (Q4 2023) Increased focus extends cash runway significantly COPENHAGEN, Den...
2023-03-23 12:51:45 ET Evaxion Biotech ( EVAX ) stock fell ~11% on Thursday despite the company saying that it has developed a new AI platform technology called ObsERV to identify new source of targets for personalized cancer therapy. The company noted that this potentiall...
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy COPENHAGEN, Denmark, March 23, 2023 (GLOBE NEWSWIRE) -- Eva...
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present ...
News, Short Squeeze, Breakout and More Instantly...
Central AI-Immunology™ Building Block: Evaxion’s proprietary in-house developed building block, EvaxMHC, is used across the AI-Immunology™ platform Improved Performance: Utilizing a state-of-the-art novel deep-learning framework as well as training on public and...
COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders...
Positive Feedback Received: An International Preliminary Report on Patentability (IPRP) indicates promising prospects for obtaining granted patents and protecting the invention Unique Attributes and Inventiveness: The feedback highlights the distinct and inventive nature of all rele...